4SC says HDAC inhibitor meets primary endpoint

4SC AG of Germany has reported that its lead cancer drug, resminostat, has met its primary endpoint in a Phase 2 trial of patients with refractory Hodgkin’s Lymphoma who had been heavily treated with other therapies prior to the trial.